Literature DB >> 14513261

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains.

Kazuhiro Imamura1, Nozomi Hishikawa, Makoto Sawada, Toshiharu Nagatsu, Mari Yoshida, Yoshio Hashizume.   

Abstract

There are numerous observations confirming that microglia expressing major histocompatibility complex (MHC) class II molecules are associated with the central nervous system (CNS) in aging and pathological conditions. In this study, we investigated the distribution of MHC class II-positive microglia in Parkinson's disease (PD) brains. The number of MHC class II-positive microglia in the substantia nigra (SN) and putamen increased as the neuronal degeneration of the SN proceeded. These cells were also ICAM-1 (CD54) and LFA-1 (CD11a) positive. The number of activated microglia not only in the SN and putamen but also in the hippocampus, transentorhinal cortex, cingulate cortex and temporal cortex in PD was significantly higher than that in the normal control. Most activated microglia persisted regardless of the presence or absence of Lewy bodies. They were frequently associated not only with alpha-synuclein-positive Lewy neurites, but also with TH-16-positive dopaminergic and WH-3-positive serotonergic neurites, as well as MAP-2- and SMI-32-positive neurites. These activated microglia were also positive for TNF-alpha and interleukin-6, which are known to have a neuroprotective function. We conclude that MHC class II-positive microglia are a sensitive index of neuropathological change and are actively associated with damaged neurons and neurites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14513261     DOI: 10.1007/s00401-003-0766-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  233 in total

1.  Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.

Authors:  Souvarish Sarkar; Hai M Nguyen; Emir Malovic; Jie Luo; Monica Langley; Bharathi N Palanisamy; Neeraj Singh; Sireesha Manne; Matthew Neal; Michelle Gabrielle; Ahmed Abdalla; Poojya Anantharam; Dharmin Rokad; Nikhil Panicker; Vikrant Singh; Muhammet Ay; Adhithiya Charli; Dilshan Harischandra; Lee-Way Jin; Huajun Jin; Srikant Rangaraju; Vellareddy Anantharam; Heike Wulff; Anumantha G Kanthasamy
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

Review 3.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

4.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 5.  Positron emission tomography imaging of neuroinflammation.

Authors:  Annachiara Cagnin; Michael Kassiou; Steve R Meikle; Richard B Banati
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

6.  Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease.

Authors:  Y Tang; T Li; J Li; J Yang; H Liu; X J Zhang; W Le
Journal:  Cell Death Differ       Date:  2013-11-08       Impact factor: 15.828

7.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

Review 8.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

10.  Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Xiaoming Hu; Dan Zhang; Hao Pang; W Michael Caudle; Yachen Li; Huiming Gao; Yuxin Liu; Li Qian; Belinda Wilson; Donato A Di Monte; Syed F Ali; Jing Zhang; Michelle L Block; Jau-Shyong Hong
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.